Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05875701 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Study of Novavax Vaccine(s) as Booster Dose After mRNA Vaccines
A Phase 3 study, sponsored by Novavax.
- Completed
- Registry status
- Phase 3
- Development phase
- 147
- Enrollment target
NCT05875701 is a Phase 3 study that has completed, run by Novavax. The registered enrollment target is 147 participants.
The verdict
NCT05875701, a Phase 3 study, has completed, sponsored by Novavax.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 147 participants
- Enrollment target
Study Summary
This is an open-label Phase 3 study evaluating the immunogenicity and safety of Novavax vaccine(s) with Matrix-M™ adjuvant (ancestral strain NVX-CoV2373 and an alternative strain and/or multivalent Novavax vaccine) as booster doses following a series of primary and booster doses of authorized/approved mRNA vaccines followed by a single booster dose of NVX-CoV2373 in the Novavax 2019nCoV-307 study (NCT05463068).
Interventions
- BIOLOGICAL NVX-CoV2373
- BIOLOGICAL SARS-CoV-2 rS antigen/Matrix-M Adjuvant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 147 participants |
| Start Date | 2023-03-28 |
| Est. Completion | 2023-11-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05875701
The ClinicalTrials.gov registry entry for NCT05875701 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 147 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novavax, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which NVX-CoV2373 is the first listed.
NCT05875701 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05875701 about?
NCT05875701 is a clinical study titled "Phase 3 Study of Novavax Vaccine(s) as Booster Dose After mRNA Vaccines". This is an open-label Phase 3 study evaluating the immunogenicity and safety of Novavax vaccine(s) with Matrix-M™ adjuvant (ancestral strain NVX-CoV2373 and an alternative strain and/or multivalent Novavax vaccine) as booster doses following a series of primary and booster doses of authorized/approv...
What is the current status of trial NCT05875701?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 147 participants. The study started on 2023-03-28. Estimated completion is 2023-11-11.
What interventions are being tested in trial NCT05875701?
The interventions under investigation include: NVX-CoV2373 (BIOLOGICAL), SARS-CoV-2 rS antigen/Matrix-M Adjuvant (BIOLOGICAL).
Who is sponsoring clinical trial NCT05875701?
This trial is sponsored by Novavax, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.